Loading...
Market
Which region will have the highest Lenacapavir adoption by end of 2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Global health reports and pharmaceutical sales data
Story
Twice-Yearly Lenacapavir Injection Shows 95% Effectiveness, 96% Risk Reduction in HIV Prevention
Dec 1, 2024, 01:35 PM
A twice-yearly injectable HIV prophylactic, Lenacapavir, has shown over 95% effectiveness in preventing HIV infections in men, according to recent studies. The injection has also been proven effective in women and offers a significant advantage over daily pills like F/TDF due to better adherence rates. Another study highlighted that a semi-annual injection reduced the risk of HIV infection by 96%. Additionally, achieving an undetectable viral load through consistent antiretroviral therapy means zero risk of transmission. This development represents a promising step toward combating HIV/AIDS, although questions remain about equitable access to the treatment.
View original story
Similar markets
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
USA • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other Regions • 25%